Search

Your search keyword '"Joly F"' showing total 2,098 results
Start Over Author "Joly F"
2,098 results on '"Joly F"'

1. Reactivating the extracellular matrix synthesis of sulfated glycosaminoglycans and proteoglycans to improve the human skin aspect and its mechanical properties

Author

Chajra H, Auriol D, Joly F, Pagnon A, Rodrigues M, Allart S, Redziniak G, and Lefevre F

Subjects
sulfated glycosaminoglycans, proteoglycans, decorin, chondroitin sulfate and heparan sulfate, Dermatology, RL1-803
Abstract

Hanane Chajra,1 Daniel Auriol,1 Francine Joly,2 Aurélie Pagnon,3 Magda Rodrigues,4 Sophie Allart,4 Gérard Redziniak,5 Fabrice Lefevre1 1Libragen, Induchem (Givaudan Active Beauty), Toulouse, 2Sephra Pharma, Puteaux, 3Novotec, Bron, 4Centre de Physiopathologie de Toulouse-Purpan, Toulouse, 5Cosmetic Inventions, Antony, France Background: The aim of this study was to demonstrate that a defined cosmetic composition is able to induce an increase in the production of sulfated glycosaminoglycans (sGAGs) and/or proteoglycans and finally to demonstrate that the composition, through its combined action of enzyme production and synthesis of macromolecules, modulates organization and skin surface aspect with a benefit in antiaging applications. Materials and methods: Gene expression was studied by quantitative reverse transcription polymerase chain reaction using normal human dermal fibroblasts isolated from a 45-year-old donor skin dermis. De novo synthesis of sGAGs and proteoglycans was determined using Blyscan™ assay and/or immunohistochemical techniques. These studies were performed on normal human dermal fibroblasts (41- and 62-year-old donors) and on human skin explants. Dermis organization was studied either ex vivo on skin explants using bi-photon microscopy and transmission electron microscopy or directly in vivo on human volunteers by ultrasound technique. Skin surface modification was investigated in vivo using silicone replicas coupled with macrophotography, and the mechanical properties of the skin were studied using Cutometer. Results: It was first shown that mRNA expression of several genes involved in the synthesis pathway of sGAG was stimulated. An increase in the de novo synthesis of sGAGs was shown at the cellular level despite the age of cells, and this phenomenon was clearly related to the previously observed stimulation of mRNA expression of genes. An increase in the expression of the corresponding core protein of decorin, perlecan, and versican and a stimulation of their respective sGAGs, such as chondroitin sulfate and heparan sulfate, were found on skin explants. The biosynthesis of macromolecules seems to be correlated at the microscopic level to a better organization and quality of the dermis, with collagen fibrils having homogenous diameters. The dermis seems to be compacted as observed on images obtained by two-photon microscopy and ultrasound imaging. At the macroscopic level, this dermis organization shows a smoothed profile similar to a younger skin, with improved mechanical properties such as firmess. Conclusion: The obtained results demonstrate that the defined cosmetic composition induces the synthesis of sGAGs and proteoglycans, which contributes to the overall dermal reorganization. This activity in the dermis in turn impacts the surface and mechanical properties of the skin. Keywords: cosmetic composition, decorin, dermis, polysaccharide

Published
2016

2. A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance 2 years later

Author

Di Meglio, A., Havas, J., Pagliuca, M., Franzoi, M.A., Soldato, D., Chiodi, C.K., Gillanders, E., Dubuisson, F., Camara-Clayette, V., Pistilli, B., Ribeiro, J., Joly, F., Cottu, P.H., Tredan, O., Bertaut, A., Ganz, P.A., Bower, J., Partridge, A.H., Martin, A.L., Everhard, S., Boyault, S., Brutin, S., André, F., Michiels, S., Pradon, C., and Vaz-Luis, I.

Published
2024
Full Text
View/download PDF

5. Avoiding the use of long-term parenteral support in patients without intestinal failure: A position paper from the European Society of Clinical Nutrition & Metabolism, the European Society of Neurogastroenterology and Motility and the Rome Foundation for Disorders of Gut–Brain Interaction

Author

Lal, S., Paine, P., Tack, J., Aziz, Q., Barazzoni, R., Cuerda, C., Jeppesen, P., Joly, F., Lamprecht, G., Mundi, M., Schneider, S., Szczepanek, K., Van Gossum, A., Wanten, G., Vanuytsel, T., and Pironi, L.

Published
2024
Full Text
View/download PDF

7. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

Author

Ledermann, J.A., Matias-Guiu, X., Amant, F., Concin, N., Davidson, B., Fotopoulou, C., González-Martin, A., Gourley, C., Leary, A., Lorusso, D., Banerjee, S., Chiva, L., Cibula, D., Colombo, N., Croce, S., Eriksson, A.G., Falandry, C., Fischerova, D., Harter, P., Joly, F., Lazaro, C., Lok, C., Mahner, S., Marmé, F., Marth, C., McCluggage, W.G., McNeish, I.A., Morice, P., Nicum, S., Oaknin, A., Pérez-Fidalgo, J.A., Pignata, S., Ramirez, P.T., Ray-Coquard, I., Romero, I., Scambia, G., Sehouli, J., Shapira-Frommer, R., Sundar, S., Tan, D.S.P., Taskiran, C., van Driel, W.J., Vergote, I., Planchamp, F., Sessa, C., and Fagotti, A.

Published
2024
Full Text
View/download PDF

10. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

Author

Ledermann, J, Matias-Guiu, X, Amant, F, Concin, N, Davidson, B, Fotopoulou, C, González-Martin, A, Gourley, C, Leary, A, Lorusso, D, Banerjee, S, Chiva, L, Cibula, D, Colombo, N, Croce, S, Eriksson, A, Falandry, C, Fischerova, D, Harter, P, Joly, F, Lazaro, C, Lok, C, Mahner, S, Marmé, F, Marth, C, Mccluggage, W, Mcneish, I, Morice, P, Nicum, S, Oaknin, A, Pérez-Fidalgo, J, Pignata, S, Ramirez, P, Ray-Coquard, I, Romero, I, Scambia, G, Sehouli, J, Shapira-Frommer, R, Sundar, S, Tan, D, Taskiran, C, van Driel, W, Vergote, I, Planchamp, F, Sessa, C, Fagotti, A, Ledermann J. A., Matias-Guiu X., Amant F., Concin N., Davidson B., Fotopoulou C., González-Martin A., Gourley C., Leary A., Lorusso D., Banerjee S., Chiva L., Cibula D., Colombo N., Croce S., Eriksson A. G., Falandry C., Fischerova D., Harter P., Joly F., Lazaro C., Lok C., Mahner S., Marmé F., Marth C., McCluggage W. G., McNeish I. A., Morice P., Nicum S., Oaknin A., Pérez-Fidalgo J. A., Pignata S., Ramirez P. T., Ray-Coquard I., Romero I., Scambia G., Sehouli J., Shapira-Frommer R., Sundar S., Tan D. S. P., Taskiran C., van Driel W. J., Vergote I., Planchamp F., Sessa C., Fagotti A., Ledermann, J, Matias-Guiu, X, Amant, F, Concin, N, Davidson, B, Fotopoulou, C, González-Martin, A, Gourley, C, Leary, A, Lorusso, D, Banerjee, S, Chiva, L, Cibula, D, Colombo, N, Croce, S, Eriksson, A, Falandry, C, Fischerova, D, Harter, P, Joly, F, Lazaro, C, Lok, C, Mahner, S, Marmé, F, Marth, C, Mccluggage, W, Mcneish, I, Morice, P, Nicum, S, Oaknin, A, Pérez-Fidalgo, J, Pignata, S, Ramirez, P, Ray-Coquard, I, Romero, I, Scambia, G, Sehouli, J, Shapira-Frommer, R, Sundar, S, Tan, D, Taskiran, C, van Driel, W, Vergote, I, Planchamp, F, Sessa, C, Fagotti, A, Ledermann J. A., Matias-Guiu X., Amant F., Concin N., Davidson B., Fotopoulou C., González-Martin A., Gourley C., Leary A., Lorusso D., Banerjee S., Chiva L., Cibula D., Colombo N., Croce S., Eriksson A. G., Falandry C., Fischerova D., Harter P., Joly F., Lazaro C., Lok C., Mahner S., Marmé F., Marth C., McCluggage W. G., McNeish I. A., Morice P., Nicum S., Oaknin A., Pérez-Fidalgo J. A., Pignata S., Ramirez P. T., Ray-Coquard I., Romero I., Scambia G., Sehouli J., Shapira-Frommer R., Sundar S., Tan D. S. P., Taskiran C., van Driel W. J., Vergote I., Planchamp F., Sessa C., and Fagotti A.

Abstract

The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June 2022 in Valencia, Spain. The CC panel included 44 experts in the management of ovarian cancer and pathology, an ESMO scientific advisor and a methodologist. The aim was to discuss new or contentious topics and develop recommendations to improve and harmonise the management of patients with ovarian cancer. Eighteen questions were identified for discussion under four main topics: (i) pathology and molecular biology, (ii) early-stage disease and pelvic mass in pregnancy, (iii) advanced stage (including older/frail patients) and (iv) recurrent disease. The panel was divided into four working groups (WGs) to each address questions relating to one of the four topics outlined above, based on their expertise. Relevant scientific literature was reviewed in advance. Recommendations were developed by the WGs and then presented to the entire panel for further discussion and amendment before voting. This manuscript focuses on the recommendation statements that reached a consensus, their voting results and a summary of evidence supporting each recommendation.

Published
2024

20. Link between postoperative ileus and anastomotic leakage: A structural equation modelling approach

Author

Abderrazak, M., Abolo, H., Abras, N., Aissou, M., Albertini, S., Alfonsi, P., Andre, A., Arimont, J.M., Arnalsteen, L., Atger, J., Attias, A., Aumont, O., Auvray, S., Bachmann, R., Barabino, G., Barsotti, P., Beauchesne, B., Beaupel, N., Beliard, A., Bellouard, A., Beloeil, H., Ben Salem, F., Benhamou, A., Billard, V., Binhas, M., Binot, D., Blache, J.L., Blet, A., Bongiovanni, J.P., Bonnal, A., Bonnet, M., Boret, H., Bossard, A.E., Bothereau, H., Bouarroudj, N., Bouayed, A., Bouchard, F., Boumadani, M., Bousquet, M., Bouygues, V., Bozio, G., Brek, A., Cadi, P., Caillon, P., Camerlo, A., Capito, C., Cardin, J.L., Castiglioni, M., Catinois, M.L., Cattan, P., Chambrier, C., Chambrier, G., Chapuis, O., Chauvin, M., Chokairi, S., Chopin Laly, X., Collange, V., Cotte, E., Cuellar, E., D'errico, E., Dahmani, S., Danan, M., De La Fontaine, C., De Wailly, P., Degauque, C., Delacoste, F., Denet, C., Denost, Q., Desaint, P., Descamps, E., Desfourneaux., V, Desmet, J., Desolneux, G., Dileon, S., Dolbeau, J.B., Douard, R., Dufour, F., Dupont-Bierre, E., Dupré, A., Entremont, A., Faucheron, J.L., Fernoux, P., Figuet, S., Finianos, A., Flamein, R., Fletcher, D., Fontes, J.P., Fourn, E., Gergeanu, S., Germain, A., Gignoux, B., Goater, P., Gres., P, Grigoroiu, M., Grillo, P., Guignard, B., Guinier, D., Guiot, J.L., Gutton, C., Hadjadj, H., Hail, K., Hausermann, M.H., Hennequin, S., Homsy-Hubert, B., Jambet, S., Janecki, T., Jannier-Guillou, V., Jaspart, J., Joly, F., Joris, J., Journe, F., Kattou, F., Kemoun, G., Khalaf, M., Klack, F., Kothonidis, K., Kurdi, O., Laforest, A., Lamblin, A., Lammens, S., Laporte, S., Launay-Savary, M.V., Le Maho, A.L., Lemée, J.M., Leonard, D., Leporrier, J., Lorin, J.L., Magne, E., Maisonnette, F., Malherbe, V., Manceau, G., Mariani, P., Massalou, D., Massard, J.L., Mauvais, F., Mbuyamba, J., Mbuyamba Katapile, J., Mehila, T., Meillat, H., Mergui, C., Michaud, P., Milou, F., Mirre, F., Mor Martinez, C., Mouchon, S., Mouilhade, F., Nguyen, Y.L., Ostermann Bucher, S., Page, M., Parent, S., Payen, A.L., Pedicone, R., Peluchon, P., Pichot-Delahaye, V., Piquard, A., Pirlet, I., Plard, L., Poiblanc, M., Poinas, G., Poincenot, J., Ponchel, C., Pontallier, A., Pop, R., Potiron, E., Proske, J.M., Prunet, B., Ras, E., Raspado, O., Raux, M., Regimbeau, J.M., Remue, C., Renacco, F., Riboud, R., Richard-Payen, A.L., Rio, D., Sage, M., Sage, P.Y., Saint Denis, M., Salaun, P., Samyn, B., Sbai Idrissi, M., Schmitt, G., Secq, E., Seddiki, A., Sens, N., Sirieix, D., Siriser, F., Tarcea, M., Tavernier, M., Tete, B., Theissen-Laval, O., Thevenot, A., Thievenaz, R., Vacher, B., Verhaeghe, R., Verrier, J.F., Vieuille, C., Voilin, C., Vuagnat, C., Zaepfel, S., Venara, Aurélien, Hamel, Jean-Francois, Beyer-Berjot, Laura, Vignaud, Timothée, and Slim, Karem

Published
2021
Full Text
View/download PDF

21. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Coleman, Robert L, Oza, Amit M, Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I, Clamp, Andrew, Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W, Gancedo, Margarita Amenedo, Fong, Peter C, Goh, Jeffrey C, O'Malley, David M, Armstrong, Deborah K, Garcia-Donas, Jesus, Swisher, Elizabeth M, Floquet, Anne, Konecny, Gottfried E, McNeish, Iain A, Scott, Clare L, Cameron, Terri, Maloney, Lara, Isaacson, Jeff, Goble, Sandra, Grace, Caroline, Harding, Thomas C, Raponi, Mitch, Sun, James, Lin, Kevin K, Giordano, Heidi, Ledermann, Jonathan A, investigators, ARIEL3, Buck, M, Dean, A, Friedlander, ML, Goh, JC, Harnett, P, Kichenadasse, G, Scott, CL, Denys, H, Dirix, L, Vergote, I, Elit, L, Ghatage, P, Oza, AM, Plante, M, Provencher, D, Weberpals, JI, Welch, S, Floquet, A, Gladieff, L, Joly, F, Leary, A, Lortholary, A, Lotz, J, Medioni, J, Tredan, O, You, B, El-Balat, A, Hänle, C, Krabisch, P, Neunhöffer, T, Pölcher, M, Wimberger, P, Amit, A, Kovel, S, Leviov, M, Safra, T, Shapira-Frommer, R, Stemmer, S, Bologna, A, Colombo, N, Lorusso, D, Pignata, S, Sabbatini, RF, Scambia, G, Tamberi, S, Zamagni, C, Fong, PC, O'Donnell, A, Gancedo, M Amenedo, Herraez, A Casado, Garcia-Donas, J, Guerra, EM, Oaknin, A, Palacio, I, Romero, I, Sanchez, A, Banerjee, SN, Clamp, A, Drew, Y, Gabra, HG, Jackson, D, Ledermann, JA, McNeish, IA, Parkinson, C, and Powell, M

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Orphan Drug, Clinical Research, Cancer, Genetics, Clinical Trials and Supportive Activities, Ovarian Cancer, Rare Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Aged, Disease-Free Survival, Double-Blind Method, Female, Follow-Up Studies, Humans, Indoles, Internationality, Maintenance Chemotherapy, Middle Aged, Molecular Targeted Therapy, Neoplasm Recurrence, Local, Ovarian Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Risk Assessment, Survival Rate, Treatment Outcome, ARIEL3 investigators, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundRucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity. In this trial we assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma.MethodsIn this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited patients from 87 hospitals and cancer centres across 11 countries. Eligible patients were aged 18 years or older, had a platinum-sensitive, high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube carcinoma, had received at least two previous platinum-based chemotherapy regimens, had achieved complete or partial response to their last platinum-based regimen, had a cancer antigen 125 concentration of less than the upper limit of normal, had a performance status of 0-1, and had adequate organ function. Patients were ineligible if they had symptomatic or untreated central nervous system metastases, had received anticancer therapy 14 days or fewer before starting the study, or had received previous treatment with a poly(ADP-ribose) polymerase inhibitor. We randomly allocated patients 2:1 to receive oral rucaparib 600 mg twice daily or placebo in 28 day cycles using a computer-generated sequence (block size of six, stratified by homologous recombination repair gene mutation status, progression-free interval after the penultimate platinum-based regimen, and best response to the most recent platinum-based regimen). Patients, investigators, site staff, assessors, and the funder were masked to assignments. The primary outcome was investigator-assessed progression-free survival evaluated with use of an ordered step-down procedure for three nested cohorts: patients with BRCA mutations (carcinoma associated with deleterious germline or somatic BRCA mutations), patients with homologous recombination deficiencies (BRCA mutant or BRCA wild-type and high loss of heterozygosity), and the intention-to-treat population, assessed at screening and every 12 weeks thereafter. This trial is registered with ClinicalTrials.gov, number NCT01968213; enrolment is complete.FindingsBetween April 7, 2014, and July 19, 2016, we randomly allocated 564 patients: 375 (66%) to rucaparib and 189 (34%) to placebo. Median progression-free survival in patients with a BRCA-mutant carcinoma was 16·6 months (95% CI 13·4-22·9; 130 [35%] patients) in the rucaparib group versus 5·4 months (3·4-6·7; 66 [35%] patients) in the placebo group (hazard ratio 0·23 [95% CI 0·16-0·34]; p

Published
2017

22. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

Author

Pignata, S, Lorusso, D, Joly, F, Gallo, C, Colombo, N, Sessa, C, Bamias, A, Salutari, V, Selle, F, Frezzini, S, De Giorgi, U, Pautier, P, Bologna, A, Orditura, M, Dubot, C, Gadducci, A, Mammoliti, S, Ray-Coquard, I, Zafarana, E, Breda, E, Favier, L, Ardizzoia, A, Cinieri, S, Largillier, R, Sambataro, D, Guardiola, E, Lauria, R, Pisano, C, Raspagliesi, F, Scambia, G, Daniele, G, Perrone, F, Pignata, Sandro, Lorusso, Domenica, Joly, Florence, Gallo, Ciro, Colombo, Nicoletta, Sessa, Cristiana, Bamias, Aristotelis, Salutari, Vanda, Selle, Frédèric, Frezzini, Simona, De Giorgi, Ugo, Pautier, Patricia, Bologna, Alessandra, Orditura, Michele, Dubot, Coraline, Gadducci, Angiolo, Mammoliti, Serafina, Ray-Coquard, Isabelle, Zafarana, Elena, Breda, Enrico, Favier, Laure, Ardizzoia, Antonio, Cinieri, Saverio, Largillier, Rémy, Sambataro, Daniela, Guardiola, Emmanuel, Lauria, Rossella, Pisano, Carmela, Raspagliesi, Francesco, Scambia, Giovanni, Daniele, Gennaro, and Perrone, Francesco

Published
2021
Full Text
View/download PDF

23. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Author

Oaknin, A, Gladieff, L, Martínez-García, J, Villacampa, G, Takekuma, M, De Giorgi, U, Lindemann, K, Woelber, L, Colombo, N, Duska, L, Leary, A, Godoy-Ortiz, A, Nishio, S, Angelergues, A, Rubio, M, Fariñas-Madrid, L, Yamaguchi, S, Lorusso, D, Ray-Coquard, I, Manso, L, Joly, F, Alarcón, J, Follana, P, Romero, I, Lebreton, C, Pérez-Fidalgo, J, Yunokawa, M, Dahlstrand, H, D'Hondt, V, Randall, L, Oaknin, Ana, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, Takekuma, Munetaka, De Giorgi, Ugo, Lindemann, Kristina, Woelber, Linn, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Nishio, Shin, Angelergues, Antoine, Rubio, Maria Jesús, Fariñas-Madrid, Lorena, Yamaguchi, Satoshi, Lorusso, Domenica, Ray-Coquard, Isabelle, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Romero, Ignacio, Lebreton, Coriolan, Pérez-Fidalgo, J Alejandro, Yunokawa, Mayu, Dahlstrand, Hanna, D'Hondt, Véronique, Randall, Leslie M, Oaknin, A, Gladieff, L, Martínez-García, J, Villacampa, G, Takekuma, M, De Giorgi, U, Lindemann, K, Woelber, L, Colombo, N, Duska, L, Leary, A, Godoy-Ortiz, A, Nishio, S, Angelergues, A, Rubio, M, Fariñas-Madrid, L, Yamaguchi, S, Lorusso, D, Ray-Coquard, I, Manso, L, Joly, F, Alarcón, J, Follana, P, Romero, I, Lebreton, C, Pérez-Fidalgo, J, Yunokawa, M, Dahlstrand, H, D'Hondt, V, Randall, L, Oaknin, Ana, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, Takekuma, Munetaka, De Giorgi, Ugo, Lindemann, Kristina, Woelber, Linn, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Nishio, Shin, Angelergues, Antoine, Rubio, Maria Jesús, Fariñas-Madrid, Lorena, Yamaguchi, Satoshi, Lorusso, Domenica, Ray-Coquard, Isabelle, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Romero, Ignacio, Lebreton, Coriolan, Pérez-Fidalgo, J Alejandro, Yunokawa, Mayu, Dahlstrand, Hanna, D'Hondt, Véronique, and Randall, Leslie M

Abstract

Background: The GOG240 trial established bevacizumab with chemotherapy as standard first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial (ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030), we aimed to evaluate the addition of an immune checkpoint inhibitor to this standard backbone. Methods: In this investigator-initiated, randomised, open-label, phase 3 trial, patients from 92 sites in Europe, Japan, and the USA with metastatic (stage IVB), persistent, or recurrent cervical cancer that was measurable, previously untreated, and not amenable to curative surgery or radiation were randomly assigned 1:1 to receive standard therapy (cisplatin 50 mg/m2 or carboplatin area under the curve of 5, paclitaxel 175 mg/m2, and bevacizumab 15 mg/kg, all on day 1 of every 3-week cycle) with or without atezolizumab 1200 mg. Treatment was continued until disease progression, unacceptable toxicity, patient withdrawal, or death. Stratification factors were previous concomitant chemoradiation (yes vs no), histology (squamous cell carcinoma vs adenocarcinoma including adenosquamous carcinoma), and platinum backbone (cisplatin vs carboplatin). Dual primary endpoints were investigator-assessed progression-free survival according to Response Evaluation Criteria in Solid Tumours version 1.1 and overall survival analysed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT03556839, and is ongoing. Findings: Between Oct 8, 2018, and Aug 20, 2021, 410 of 519 patients assessed for eligibility were enrolled. Median progression-free survival was 13·7 months (95% CI 12·3–16·6) with atezolizumab and 10·4 months (9·7–11·7) with standard therapy (hazard ratio [HR]=0·62 [95% CI 0·49–0·78]; p<0·0001); at the interim overall survival analysis, median overall survival was 32·1 months (95% CI 25·3–36·8) versus 22·8 months (20·3–28·0), respectively (HR 0·68 [95% CI 0·52–0·88]; p=0·0046). Grade 3 or worse adverse events occurred in 79% of patient

Published
2024

24. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

Author

Ledermann, J. A., Matias-Guiu, X., Amant, F., Concin, N., Davidson, B., Fotopoulou, C., González-Martin, A., Gourley, C., Leary, A., Lorusso, Domenica, Banerjee, S., Chiva, L., Cibula, D., Colombo, N., Croce, S., Eriksson, A. G., Falandry, C., Fischerova, D., Harter, P., Joly, F., Lazaro, C., Lok, C., Mahner, S., Marmé, F., Marth, C., Mccluggage, W. G., Mcneish, I. A., Morice, P., Nicum, S., Oaknin, A., Pérez-Fidalgo, J. A., Pignata, S., Ramirez, P. T., Ray-Coquard, I., Romero, I., Scambia, Giovanni, Sehouli, J., Shapira-Frommer, R., Sundar, S., Tan, D. S. P., Taskiran, C., van Driel, W. J., Vergote, I., Planchamp, F., Sessa, C., Fagotti, Anna, Lorusso, D., Scambia, G. (ORCID:0000-0003-2758-1063), Fagotti, A. (ORCID:0000-0001-5579-335X), Ledermann, J. A., Matias-Guiu, X., Amant, F., Concin, N., Davidson, B., Fotopoulou, C., González-Martin, A., Gourley, C., Leary, A., Lorusso, Domenica, Banerjee, S., Chiva, L., Cibula, D., Colombo, N., Croce, S., Eriksson, A. G., Falandry, C., Fischerova, D., Harter, P., Joly, F., Lazaro, C., Lok, C., Mahner, S., Marmé, F., Marth, C., Mccluggage, W. G., Mcneish, I. A., Morice, P., Nicum, S., Oaknin, A., Pérez-Fidalgo, J. A., Pignata, S., Ramirez, P. T., Ray-Coquard, I., Romero, I., Scambia, Giovanni, Sehouli, J., Shapira-Frommer, R., Sundar, S., Tan, D. S. P., Taskiran, C., van Driel, W. J., Vergote, I., Planchamp, F., Sessa, C., Fagotti, Anna, Lorusso, D., Scambia, G. (ORCID:0000-0003-2758-1063), and Fagotti, A. (ORCID:0000-0001-5579-335X)

Abstract

The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June 2022 in Valencia, Spain. The CC panel included 44 experts in the management of ovarian cancer and pathology, an ESMO scientific advisor and a methodologist. The aim was to discuss new or contentious topics and develop recommendations to improve and harmonise the management of patients with ovarian cancer. Eighteen questions were identified for discussion under four main topics: (i) pathology and molecular biology, (ii) early-stage disease and pelvic mass in pregnancy, (iii) advanced stage (including older/frail patients) and (iv) recurrent disease. The panel was divided into four working groups (WGs) to each address questions relating to one of the four topics outlined above, based on their expertise. Relevant scientific literature was reviewed in advance. Recommendations were developed by the WGs and then presented to the entire panel for further discussion and amendment before voting. This manuscript focuses on the recommendation statements that reached a consensus, their voting results and a summary of evidence supporting each recommendation.

Published
2024

25. Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network

Author

Derquin, F., Floquet, A., Hardy-Bessard, A.C., Edeline, J., Lotz, J.P., Alexandre, J., Pautier, P., Angeles, M.A., Delanoy, N., Lefeuvre-Plesse, C., Cancel, M., Treilleux, I., Augereau, P., Lavoue, V., Kalbacher, E., Berton Rigaud, D., Selle, F., Nadeau, C., Gantzer, J., Joly, F., Guillemet, C., Pomel, C., Favier, L., Abdeddaim, C., Venat-Bouvet, L., Provansal, M., Fabbro, M., Kaminsky, M.C., Lortholary, A., Lecuru, F., Coquard, I. Ray, and de La Motte Rouge, T.

Published
2020
Full Text
View/download PDF

26. The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study

Author

Lenck, C., Chopin, N., Gouy, S., Bonsang-Kitzis, H., Martinez-Gomez, C., Radosevic-Robin, N., Martin, S., Lefeuvre-plesse, C., Lambaudie, E., Leblanc, E., Guyon, F., Classe, J.-M., Ramanah, R., Beurrier, F., Angeles, M.A., Pomel, C., Joly, F., de la Motte Rouge, T., Provansal, M., Lesoin, A., Floquet, A., Berton, D., Kalbacher, E., Chakiba, C., Meeus, P., Selle, F., Treilleux, I., Lecuru, F., Pautier, P., and Ray-Coquard, I.

Published
2020
Full Text
View/download PDF

27. Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG symptom benefit study (SBS)

Author

Roncolato, F.T., O'Connell, R.L., Joly, F., Lanceley, A., Hilpert, F., Buizen, L., Okamoto, A., Aotani, E., Salutari, V., Donnellan, P., Oza, A., Avall-Lundqvist, E., Berek, J., Fehm, T., Ledermann, J., Roemer-Becuwe, C., Stockler, M.R., King, M.T., and Friedlander, M.L.

Published
2020
Full Text
View/download PDF

34. Glepaglutide efficacy and safety in short bowel syndrome patients without or with colon-in-continuity: Results of ease sbs 1 phase 3 trial

Author

Pape, U.F., primary, Vanuytsel, T., additional, Subramanian, S., additional, Joly, F., additional, Wanten, G., additional, Lamprecht, G., additional, Kunecki, M., additional, Rahman, F., additional, Nielsen, T.S., additional, Graff, L.B., additional, Berner-Hansen, M., additional, Mercer, D.F., additional, and Jeppesen, P.B., additional

Published
2023
Full Text
View/download PDF

38. Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial

Author

Sabatier, R, Rousseau, F, Joly, F, Cropet, C, Montegut, C, Frindte, J, Cinieri, S, Guerra Alia, E, Polterauer, S, Yoshida, H, Vergote, I, Colombo, N, Hietanen, S, Largillier, R, Canzler, U, Gratet, A, Marme, F, Favier, L, Pujade-Lauraine, E, Ray-Coquard, I, Sabatier R., Rousseau F., Joly F., Cropet C., Montegut C., Frindte J., Cinieri S., Guerra Alia E. M., Polterauer S., Yoshida H., Vergote I., Colombo N., Hietanen S., Largillier R., Canzler U., Gratet A., Marme F., Favier L., Pujade-Lauraine E., Ray-Coquard I., Sabatier, R, Rousseau, F, Joly, F, Cropet, C, Montegut, C, Frindte, J, Cinieri, S, Guerra Alia, E, Polterauer, S, Yoshida, H, Vergote, I, Colombo, N, Hietanen, S, Largillier, R, Canzler, U, Gratet, A, Marme, F, Favier, L, Pujade-Lauraine, E, Ray-Coquard, I, Sabatier R., Rousseau F., Joly F., Cropet C., Montegut C., Frindte J., Cinieri S., Guerra Alia E. M., Polterauer S., Yoshida H., Vergote I., Colombo N., Hietanen S., Largillier R., Canzler U., Gratet A., Marme F., Favier L., Pujade-Lauraine E., and Ray-Coquard I.

Abstract

Background: The phase III PAOLA-1/ENGOT-ov25 study (NCT02477644) showed that addition of olaparib to bevacizumab maintenance improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer. We evaluated maintenance olaparib plus bevacizumab in older patients in PAOLA-1. Methods: Baseline clinical and molecular data, and PFS, were compared between older (aged ≥65 years) and younger patients (<65 years). Factors associated with olaparib efficacy, and safety in age subgroups, were also assessed. Results: Of 806 randomised patients, 292 (36.2%) were ≥65 years. A lower proportion of older versus younger patients had an Eastern Cooperative Oncology Group performance status of 0 (61.0% versus 76.2%) and upfront surgery (42.0% versus 55.7%). Older patients were less likely to have a BRCA1/2 mutation (17.1% versus 36.7%) or homologous recombination deficiency-positive status (34.1% versus 55.7%). After median follow-up of 22.1 months, median PFS was 21.6 months with olaparib versus 16.6 months with placebo in the older population (hazard ratio [HR] 0.55, 95% confidence interval [CI] 0.41–0.75), comparable with the younger population (median 22.9 versus 16.9 months; HR 0.61, 95% CI 0.49–0.77). PFS benefits were observed in patients with a BRCA mutation or homologous recombination deficiency-positive tumours. Incidence of olaparib-related grade ≥3 adverse events in older patients was comparable with that of younger patients (36.8% versus 31.7%) although hypertension and anaemia were more common in older patients. No treatment-related deaths occurred in older patients receiving olaparib. Conclusion: Older patients enrolled in PAOLA-1 achieved similar PFS benefits compared with younger patients, with a similar safety profile.

Published
2023

39. COVID-19 infection in patients on long-term home parenteral nutrition for chronic intestinal failure

Author

Pironi, L, Jezerski, D, Sobocki, J, Lal, S, Vanuytsel, T, Theilla, M, Sasdelli, A, Chambrier, C, Matysiak, K, Aimasso, U, Rasmussen, H, Jukes, A, Kunecki, M, Seguy, D, Schneider, S, Daniels, J, Poullenot, F, Mundi, M, Matras, P, Folwarski, M, Crivelli, A, Wyer, N, Ellegard, L, Santarpia, L, Arvanitakis, M, Spaggiari, C, Lamprecht, G, Guglielmi, F, Lezo, A, Layec, S, Boluda, E, Guz-Mark, A, Gandullia, P, Cuerda, C, Osland, E, Spagnuolo, M, Krznaric, Z, Masconale, L, Chapman, B, Maiz-Jimenez, M, Orlandoni, P, Martins da Rocha, M, Virgili-Casas, M, Doitchinova-Simeonova, M, Czako, L, Van Gossum, A, D'Antiga, L, Ee, L, Warodomwichit, D, Taus, M, Kolacek, S, Thibault, R, Verlato, G, Serralde-Zuniga, A, Botella-Carretero, J, Aguayo, P, Olveira, G, Chomtho, S, Pisprasert, V, Moisejevs, G, Murillo, A, Jauregui, M, Diez, M, Jahit, M, Densupsoontorn, N, Tamer, A, Brillanti, G, Joly, F, Pironi L., Jezerski D., Sobocki J., Lal S., Vanuytsel T., Theilla M., Sasdelli A. S., Chambrier C., Matysiak K., Aimasso U., Rasmussen H. H., Jukes A., Kunecki M., Seguy D., Schneider S. M., Daniels J., Poullenot F., Mundi M. S., Matras P., Folwarski M., Crivelli A., Wyer N., Ellegard L., Santarpia L., Arvanitakis M., Spaggiari C., Lamprecht G., Guglielmi F. W., Lezo A., Layec S., Boluda E. R., Guz-Mark A., Gandullia P., Cuerda C., Osland E., Spagnuolo M. I., Krznaric Z., Masconale L., Chapman B., Maiz-Jimenez M., Orlandoni P., Martins da Rocha M. H., Virgili-Casas M. N., Doitchinova-Simeonova M., Czako L., Van Gossum A., D'Antiga L., Ee L. C., Warodomwichit D., Taus M., Kolacek S., Thibault R., Verlato G., Serralde-Zuniga A. E., Botella-Carretero J. I., Aguayo P. S., Olveira G., Chomtho S., Pisprasert V., Moisejevs G., Murillo A. Z., Jauregui M. E. P., Diez M. B., Jahit M. S., Densupsoontorn N., Tamer A., Brillanti G., Joly F., Pironi, L, Jezerski, D, Sobocki, J, Lal, S, Vanuytsel, T, Theilla, M, Sasdelli, A, Chambrier, C, Matysiak, K, Aimasso, U, Rasmussen, H, Jukes, A, Kunecki, M, Seguy, D, Schneider, S, Daniels, J, Poullenot, F, Mundi, M, Matras, P, Folwarski, M, Crivelli, A, Wyer, N, Ellegard, L, Santarpia, L, Arvanitakis, M, Spaggiari, C, Lamprecht, G, Guglielmi, F, Lezo, A, Layec, S, Boluda, E, Guz-Mark, A, Gandullia, P, Cuerda, C, Osland, E, Spagnuolo, M, Krznaric, Z, Masconale, L, Chapman, B, Maiz-Jimenez, M, Orlandoni, P, Martins da Rocha, M, Virgili-Casas, M, Doitchinova-Simeonova, M, Czako, L, Van Gossum, A, D'Antiga, L, Ee, L, Warodomwichit, D, Taus, M, Kolacek, S, Thibault, R, Verlato, G, Serralde-Zuniga, A, Botella-Carretero, J, Aguayo, P, Olveira, G, Chomtho, S, Pisprasert, V, Moisejevs, G, Murillo, A, Jauregui, M, Diez, M, Jahit, M, Densupsoontorn, N, Tamer, A, Brillanti, G, Joly, F, Pironi L., Jezerski D., Sobocki J., Lal S., Vanuytsel T., Theilla M., Sasdelli A. S., Chambrier C., Matysiak K., Aimasso U., Rasmussen H. H., Jukes A., Kunecki M., Seguy D., Schneider S. M., Daniels J., Poullenot F., Mundi M. S., Matras P., Folwarski M., Crivelli A., Wyer N., Ellegard L., Santarpia L., Arvanitakis M., Spaggiari C., Lamprecht G., Guglielmi F. W., Lezo A., Layec S., Boluda E. R., Guz-Mark A., Gandullia P., Cuerda C., Osland E., Spagnuolo M. I., Krznaric Z., Masconale L., Chapman B., Maiz-Jimenez M., Orlandoni P., Martins da Rocha M. H., Virgili-Casas M. N., Doitchinova-Simeonova M., Czako L., Van Gossum A., D'Antiga L., Ee L. C., Warodomwichit D., Taus M., Kolacek S., Thibault R., Verlato G., Serralde-Zuniga A. E., Botella-Carretero J. I., Aguayo P. S., Olveira G., Chomtho S., Pisprasert V., Moisejevs G., Murillo A. Z., Jauregui M. E. P., Diez M. B., Jahit M. S., Densupsoontorn N., Tamer A., Brillanti G., and Joly F.

Abstract

Background and aims: To investigate the incidence and the severity of COVID-19 infection in patients enrolled in the database for home parenteral nutrition (HPN) for chronic intestinal failure (CIF) of the European Society for Clinical Nutrition and Metabolism (ESPEN). Methods: Period of observation: March 1st, 2020 March 1st, 2021. Inclusion criteria: patients included in the database since 2015 and still receiving HPN on March 1st, 2020 as well as new patients included in the database during the period of observation. Data related to the previous 12 months and recorded on March 1st 2021: 1) occurrence of COVID-19 infection since the beginning of the pandemic (yes, no, unknown); 2) infection severity (asymptomatic; mild, no-hospitalization; moderate, hospitalization no-ICU; severe, hospitalization in ICU); 3) vaccinated against COVID-19 (yes, no, unknown); 4) patient outcome on March 1st 2021: still on HPN, weaned off HPN, deceased, lost to follow up. Results: Sixty-eight centres from 23 countries included 4680 patients. Data on COVID-19 were available for 55.1% of patients. The cumulative incidence of infection was 9.6% in the total group and ranged from 0% to 21.9% in the cohorts of individual countries. Infection severity was reported as: asymptomatic 26.7%, mild 32.0%, moderate 36.0%, severe 5.3%. Vaccination status was unknown in 62.0% of patients, non-vaccinated 25.2%, vaccinated 12.8%. Patient outcome was reported as: still on HPN 78.6%, weaned off HPN 10.6%, deceased 9.7%, lost to follow up 1.1%. A higher incidence of infection (p = 0.04), greater severity of infection (p < 0.001) and a lower vaccination percentage (p = 0.01) were observed in deceased patients. In COVID-19 infected patients, deaths due to infection accounted for 42.8% of total deaths. Conclusions: In patients on HPN for CIF, the incidence of COVID-19 infection differed greatly among countries. Although the majority of cases were reported to be asymptomatic or have mild symptoms only, COV

Published
2023

40. Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis

Author

Ferreira, A.R., Di Meglio, A., Pistilli, B., Gbenou, A.S., El-Mouhebb, M., Dauchy, S., Charles, C., Joly, F., Everhard, S., Lambertini, M., Coutant, C., Cottu, P., Lerebours, F., Petit, T., Dalenc, F., Rouanet, P., Arnaud, A., Martin, A., Berille, J., Ganz, P.A., Partridge, A.H., Delaloge, S., Michiels, S., Andre, F., and Vaz-Luis, I.

Published
2019
Full Text
View/download PDF

42. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Author

Baert, T., Banerjee, S., Belaroussi, I., Blecharz, P., Bruchim, I., Cibula, D., Colombo, N., Concin, N., Davidson, B., Dashora, A., Devouassoux-Shisheboran, M., du Bois, A., Ferrero, A., Glasspool, R., González-Martin, A., Heinzelmann-Schwarz, V., Joly, F., Kim, J.W., Kridelka, F., Ledermann, J., Lorusso, D., Mahner, S., McCluggage, W.G., McNeish, I., Mikami, M., Mirza, M.R., Morice, P., Nicum, S., Olbrecht, S., O’Donnell, D.M., Pautier, P., Planchamp, F., Pignata, S., Querleu, D., Ray-Coquard, I., Rodolakis, A., Sehouli, J., Selcukbiricik, F., Sessa, C., Singh, N., Tan, D.S.P., Timmerman, D., Tognon, G., van der Velden, J., Vergote, I., Witteveen, P.O., and Zeimet, A.G.

Published
2019
Full Text
View/download PDF

43. Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study

Author

Joly, F., Ahmed-Lecheheb, D., Kalbacher, E., Heutte, N., Clarisse, B., Grellard, J.M., Gernier, F., Berton-Rigaud, D., Tredan, O., Fabbro, M., Savoye, A.M., Kurtz, J.E., Alexandre, J., Follana, P., Delecroix, V., Dohollou, N., Roemer-Becuwe, C., De Rauglaudre, G., Lortholary, A., Prulhiere, K., Lesoin, A., Zannetti, A., N’Guyen, S., Trager-Maury, S., Chauvenet, L., Abadie Lacourtoisie, S., Gompel, A., Lhommé, C., Floquet, A., and Pautier, P.

Published
2019
Full Text
View/download PDF

44. Species richness: A pivotal factor mediating the effects of land use intensification and climate on grassland multifunctionality.

Author

Allart, L., Dumont, B., Joly, F., Mosnier, C., Alvarez, G., Galliot, J.‐N., Luna, D., Pottier, J., and Gross, N.

Subjects
GRASSLANDS, CLIMATE change, SPECIES diversity, ENDANGERED ecosystems, LAND use, GLOBAL warming
Abstract

Copyright of Journal of Applied Ecology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

48. Expression III: patients’ expectations and preferences regarding physician–patient relationship and clinical management—results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries

Author

Oskay-Özcelik, G., Alavi, S., Richter, R., Keller, M., Chekerov, R., Cecere, S.C., Cormio, G., Joly, F., Kurtz, J.E., du Bois, A., Maciejewski, M., Jedryka, M., Vergote, I., Van Nieuwenhuysen, E., Casado, A., Mendiola, C., Achimas-Cadariu, P., Vlad, C., Reimer, D., Zeimet, A.G., Friedlander, M., and Sehouli, J.

Published
2018
Full Text
View/download PDF

50. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Buck, M, Dean, A, Friedlander, M L, Goh, J C, Harnett, P, Kichenadasse, G, Scott, C L, Denys, H, Dirix, L, Vergote, I, Elit, L, Ghatage, P, Oza, A M, Plante, M, Provencher, D, Weberpals, J I, Welch, S, Floquet, A, Gladieff, L, Joly, F, Leary, A, Lortholary, A, Lotz, J, Medioni, J, Tredan, O, You, B, El-Balat, A, Hänle, C, Krabisch, P, Neunhöffer, T, Pölcher, M, Wimberger, P, Amit, A, Kovel, S, Leviov, M, Safra, T, Shapira-Frommer, R, Stemmer, S, Bologna, A, Colombo, N, Lorusso, D, Pignata, S, Sabbatini, R F, Scambia, G, Tamberi, S, Zamagni, C, Fong, P C, O'Donnell, A, Gancedo, M Amenedo, Herraez, A Casado, Garcia-Donas, J, Guerra, E M, Oaknin, A, Palacio, I, Romero, I, Sanchez, A, Banerjee, S N, Clamp, A, Drew, Y, Gabra, H G, Jackson, D, Ledermann, J A, McNeish, I A, Parkinson, C, Powell, M, Aghajanian, C, Armstrong, D K, Birrer, M J, Buss, M K, Chambers, S K, Chen, L-m, Coleman, R L, Holloway, R W, Konecny, G E, Ma, L, Morgan, M A, Morris, R T, Mutch, D G, O'Malley, D M, Slomovitz, B M, Swisher, E M, Vanderkwaak, T, Vulfovich, M, Coleman, Robert L, Oza, Amit M, Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I, Clamp, Andrew, Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W, Gancedo, Margarita Amenedo, Fong, Peter C, Goh, Jeffrey C, O'Malley, David M, Armstrong, Deborah K, Garcia-Donas, Jesus, Swisher, Elizabeth M, Floquet, Anne, Konecny, Gottfried E, McNeish, Iain A, Scott, Clare L, Cameron, Terri, Maloney, Lara, Isaacson, Jeff, Goble, Sandra, Grace, Caroline, Harding, Thomas C, Raponi, Mitch, Sun, James, Lin, Kevin K, Giordano, Heidi, and Ledermann, Jonathan A

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results